Carbon Dioxide（CO2）Fractional Laser Plus Photodynamic Therapy in Female Patients With Vulvar Lichen Sclerosus

Launched by XIJING HOSPITAL · Feb 7, 2022

Keywords

ClinConnect Summary

This is a randomized, open-labeled, assessor-blind, parallel control study. 134 enrolled patients will be randomized to apply either topical 0.1% corticosteroid mometasone furoate(MMF) ointment or photodynamic therapy.

For patients who receive photodynamic therapy, lesions will be symmetrically randomized into two sides. One side will receive CO2 fractional laser before photodynamic therapy, while the other side will receive photodynamic therapy only.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18-60 (inclusive), female patients;
• • 2. present typical clinical manifestations of of vulvar lichen sclerosus, confirmed by histopathological examination;
• • 3. Volunteer to participate in this study and sign an informed consent form.
• Exclusion Criteria:
• • 1. Severe organic diseases, such as severe heart, lung, liver, kidney insufficiency, coagulation dysfunction, etc.;
• • 2. Suffer from autoimmune diseases, such as systemic lupus erythematosus, thyroid disease, etc.;
• • 3. Suffer from photoallergic diseases, such as chronic photosensitivity dermatitis, plant solar dermatitis;
• • 4. People with porphyria or porphyria allergy;
• • 5. Suffer from psychiatric diseases, such as schizophrenia, etc.;
• • 6. Those who are undergoing systemic treatment due to malignant tumor diseases, such as cervical cancer;
• • 7. It is confirmed by laboratory pathogenic screening to have syphilis, HIV, and other sexually transmitted diseases or viral hepatitis;
• • 8. Patients with current bacterial or fungal infections in the anus and genitals;
• • 9. Women of childbearing age who have pregnancy plans, are pregnant, or are breastfeeding during the observation period of this study;
• • 10. Patients who are systematically using glucocorticoids, immunosuppressants, and anticoagulants;
• • 11. Use glucocorticoids for topical or local injection and calcineurin inhibitors for topical use within 4 weeks;
• • 12. Those who are allergic to 5-aminolevulinic acid or its base, mometasone furoate or its base;
• • 13. Other situations that the investigator considers inappropriate to participate in the clinical study.